Table 4 Secondary outcome measures
Outcome | No. of trials | No. of events/total patients in cohort | Effect estimate (95% CI) | I 2 | |
|---|---|---|---|---|---|
Omega-3 PUFA | Control | ||||
2 | 6/156 | 8/132 | Peto OR, 0.64 (0.22, 1.88) | 0% | |
2 | 5/156 | 7/132 | Peto OR, 0.60 (0.19, 1.90) | 0% | |
Stroke (Leng 1998 [34]) | 1 | 3/60 | 1/60 | Peto OR, 2.79 (0.38, 20.31) | NE |
Angina (Ishikawa 2010 [38]) | 1 | 5/117 | 8/106 | RR, 0.57 (0.19, 1.68) | NE |
Adverse Effects | Â | Â | Â | Â | Â |
2 | 17/76 | 21/76 | RR 0.81 (0.48, 1.38) | NE | |
 Gastrointestinal Upset (Leng 1998 [34]) | 1 | 30/60 | 19/60 | RR 1.58 (1.01, 2.48) | NE |
Revascularization Surgery (Leng 1998 [34], Ishikawa 2010 [38]) | 2 | 9/156 | 13/132 | RR, 0.81 (0.13, 4.91) | 59% |
Amputation (Leng 1998 [34]) | 1 | 0/60 | 1/60 | Peto OR, 0.14 (0.00, 6.82) | NE |
Pain-Free Walking Distance (Gans 1990 [37], Leng 1998 [34], Carrero 2005 [35], Carrero 2006 [36]) | 4 | 95 | 88 | MD, 115.40 (-42.24, 273.05) | 89% |
Maximum Walking Distance (Gans 1990 [37]) | 1 | 16 | 16 | MD, -26.00 (-71.92, 19.92) | NE |